Amelioration of sulfur mustard skin injury following a topical treatment with a mixture of a steroid and a NSAID

Journal of Applied Toxicology

Volumn 24, Issue 2, 2004, Pages 107-113

  Dachir, Shlomit ^a   Fishbeine, Eliezer ^a   Meshulam, Yakov ^a   Sahar, Rita ^a   Chapman, Shira ^a   Amir, Adina ^a   Kadar, Tamar ^a  

^a ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH   (Israel)

Author keywords

Chromameter; Inflammation; NSAID; Steroids; Sulfur mustard

Indexed keywords

ADEXONE; DEXAMETHASONE; DICLOFENAC DIETHYLAMINE; KETAMINE; MUSTARD GAS; NONSTEROID ANTIINFLAMMATORY AGENT; PENTOBARBITAL; PROSTAGLANDIN E; STEROID; XYLAZINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCHEMISTRY; BIOPSY TECHNIQUE; CELL DAMAGE; CONTROLLED STUDY; CONVALESCENCE; CYTOTOXICITY; DERMIS; DRUG EFFICACY; DRUG MIXTURE; EAR INJURY; EPIDERMIS; EPITHELIUM CELL; EXPOSURE; HISTOPATHOLOGY; HOMOGENATE; MEDICAL RESEARCH; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN DEFECT; SKIN EDEMA; SKIN INFLAMMATION; SKIN INJURY;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHEMICAL WARFARE AGENTS; DEXAMETHASONE; DICLOFENAC; DRUG THERAPY, COMBINATION; EAR, EXTERNAL; EDEMA; GLUCOCORTICOIDS; INFLAMMATION; MICE; MICE, INBRED STRAINS; MUSTARD GAS; PROSTAGLANDINS E; SKIN;

EID: 1842817583     PISSN: 0260437X     EISSN: None     Source Type: Journal    
DOI: 10.1002/jat.955     Document Type: Article

References (28)

1. Ahluwalia A. 1998. Topical glucocorticoids and the skin-mechanisms of action: an update. Mediat. Inflamm. 7: 183-193.
2. Arroyo CM. 1998. A novel multiple therapeutic approach (MTA) for suppression of the inflammatory and immunology responses observed in vesicant injury. In Proceedings of the 1998 Medical Defense Bioscience Review. US Army Medical Research Institute of Chemical Defense: Maryland.
3. Arshinoff S. 1994. The role of NSAIDs in ophthalmic laser procedures. In Proceedings of the Ophthalmic NSAID Roundtable at the American Academy of Ophthalmology's 96th Annual Meeting, Solomon LD (ed.). Medicopea Int. San Francisco, USA: 59-68.
4. Babin MC, Ricketts K, Skvorak JP, Gazaway M, Mitcheltree LW, Casillas RP. 2000. Systemic administration of candidate antivesicants to protect against topically applied sulfur mustard in the mouse ear vesicant model (MEVM). J. Appl. Toxicol. 20: S141-S144.
5. Barranco VP. 1991. Mustard gas and the dermatologist. Int. J. Dermatol. 30: 684-686.
6. Bradford M. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254.
7. Buritova J, Honore P, Chapman V, Besson JM. 1996. Enhanced effects of co-administered dexamethasone and diclofenac on inflammatory pain processing and associated spinal c-fos expression in the rat. Pain 64: 559-568.
8. Casillas RP, Sabourin CL. 1998. Immunohistochemical evaluation of inflammatory cytokines in mouse skin following sulfur mustard exposure. In Proceedings of the 1998 Medical Defense Bioscience Review. US Army Medical Research Institute of Chemical Defense: Maryland.
9. Casillas RP, Mitcheltree LW, Stemler FW. 1997. The mouse ear model of cutaneous sulfur mustard injury. Toxicol. Methods 7: 381-397.
10. Casillas RP, Kiser RC, Truxall JA, Singer AIW, Shumaker SM, Niemuth NA, Ricketts KM, Mitcheltree LW, Castrejo LR, Blank JA. 2000. Therapeutic approaches to dermatotoxicity by sulfur mustard. I. Modulation of sulfur mustard-induced cutaneous injury in the mouse ear vesicant model. J. Appl. Toxicol. 20: S145-S151.
11. Cowan FM, Broomfield CA. 1993. Putative roles of inflammation in the dermatopathology of sulfur mustard. Cell Biol. Toxicol. 9: 201-213.
12. Dachir S, Fishbeine E, Meshulam Y, Sahar R, Amir A, Kadar T. 2002. Potential anti-inflammatory treatments against cutaneous sulfur mustard injury using the mouse ear vesicant model. Hum. Exp. Toxicol. 21: 197-203.
13. Kadar T, Fishbeine E, Sahar R, Liani H, Simon G, Gilat E. 1994. Studies on the pathogenesis of sulfur mustard induced vesication in the pig skin. Proc. Israel/USA Bilateral 'Shoresh' Meeting, Israel.
14. Kiser RC, Moore DM, Tussing M, Toft II JD, Niemuth NA, Olson CT, Babin MC, Casillas RP. 2000. Post-treatment protection against cutaneous sulfur mustard exposure using the mouse ear vesicant model (MEVM). In Proceedings of the 2000 Medical Defense Bioscience Review. US Army Medical Research Institute of Chemical Defense: Maryland; 746-753.
15. Kremer J. 2000. From prostaglandin replacement to specific COX-2 inhibition: a critical appraisal. J. Rheumatol. 27(suppl. 60): 9-12.
16. Mellor SG, Rice P, Cooper GJ. 1991. Vesicant burns. Br. J. Plast. Surg. 44: 434-437.
17. Monteiro-Riviere NA, Inman AO. 1997. Ultrastructural characterization of sulfur mustard-induced vesication in isolated perfused porcine skin. Microsc. Res. Tech. 37: 229-241.
18. Papirmeister B, Gross CL, Meier HL, Petrali JP, Johnson JB. 1985. Molecular basis for mustard-induced vesication. Fundam. Appl. Toxicol. 5: S134-S149.
19. Petrali JP, Oglesby-Megee S. 1997. Toxicity of mustard gas skin lesion. Microsc. Res. Tech. 37: 221-228.
20. Petrali JP, Kan RK, Hamilton TA, Pleva CM. 2002. Mustard gas-induced lesions: morphological expressions. In Proceedings of the 2002 Medical Defense Bioscience Review. US Army Medical Research Institute of Chemical Defense: Maryland; 660.
21. Ray R, Legere RH, Broomfield CA. 1997. Sulfur mustard-induced decrease in membrane fluidity. J Am Cell Toxicol 15(suppl. 2): 52-58.
22. Ricketts KM, Santai CT, France JA, Graziosi AM, Doyel TD, Gazaway MY, Casillas RP. 2000. Inflammatory cytokine response in sulfur mustard-exposed mouse skin. J. Appl. Toxicol. 20: S73-S76.
23. Smith KJ, Hurst CG, Moeller RB, Skelton HG, Sidell FR. 1995. Sulfur mustard: its continuing threat as a chemical warfare agent, the cutaneous lesions induced, progress in understanding its mechanism of action, its long-term health effects, and new developments for protection and therapy. J. Am. Acad. Dermatol. 32: 765-767.
24. Vane JR. 1971. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biol. 231: 232-235.
25. Vane J, Botting R. 1987. Inflammation and the mechanism of action of anti-inflammatory drugs. FASEB J. 1: 89-96.
26. Vane JR, Botting RM. 1998. Anti-inflammatory drugs and their mechanism of action. Inflamm. Res. 47: S78-S87.
27. Willems JL. 1989. Clinical management of mustard gas casualties. Ann. Med. Milita. 3(suppl.): 1-61.
28. Yourick JJ, Dawson JS, Mitcheltree LW. 1995. Reduction of erythema in hairless guinea pigs after cutaneous sulfur mustard vapor exposure by pretreatment with niacinamide, promethazine and indomethacin. J. Appl. Toxicol. 15: 133-138.